Figure 1
![Figure 1. Treatment schedules of studies AML-BFM-1998 and AML-BFM-2004 in standard-risk patients. Induction: AIE indicates cytarabine/idarubicin/etoposide or randomized with ADxE; and ADxE, cytarabine/liposomal daunorubicin/etoposide. Second induction: HAM indicates high-dose cytarabine [3 g/m2]/mitoxantrone. Consolidation: AI indicates cytarabine [0.5 g/m2]/idarubicin; and hAM, high-dose cytarabine [1 g/m2]/mitoxantrone. Intensification: HAE indicates high-dose cytarabine [3 g/m2]/etoposide; and CNS-RT, cranial irradiation.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/20/10.1182_blood-2011-07-364661/4/zh89991181870001.jpeg?Expires=1722730547&Signature=exoTpf-eHJpmUzabU7~779TC2KyN2Ack0iEi94XnBFrXNjNYCPtPFnXxvOoOfYLB123lLYXwI~y4rW6wKQ9AVH3MXVI~Hn8NHiGLM36B7KV4BL9PD3-c4WLISGTh7Z-inxA4nlQT7xAf~KTpESRBMaRY-wJIBiScaqXz8A1pXd~ZyEZ07QOakqiSDKW4EIJQX~HlrVXB18EfjxiWEOs0F6n649TIU9AIa43xSIV6SrxflhXE1vBgMVZVZ2Fup9syBPBKUKe5cGcdgZiXIconzk660PwZo1uDNveMHEEwGhesqTcfzYO2QlDYVH-Z-I6B1C3cn5QKGvI9ER1BogjwIA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Treatment schedules of studies AML-BFM-1998 and AML-BFM-2004 in standard-risk patients. Induction: AIE indicates cytarabine/idarubicin/etoposide or randomized with ADxE; and ADxE, cytarabine/liposomal daunorubicin/etoposide. Second induction: HAM indicates high-dose cytarabine [3 g/m2]/mitoxantrone. Consolidation: AI indicates cytarabine [0.5 g/m2]/idarubicin; and hAM, high-dose cytarabine [1 g/m2]/mitoxantrone. Intensification: HAE indicates high-dose cytarabine [3 g/m2]/etoposide; and CNS-RT, cranial irradiation.
